RxDoctor Payments Data

Arshia Noori, MD

Clinical Cardiac Electrophysiology · Los Angeles, CANPI 1043246572

Payments from drug & device makers

$17,044in general payments, 2019–2025

Across 454 payments — averaging $37.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Boston Scientific$3K
  • Medtronic$2K
  • Amgen$1K
  • Novartis$1K
  • Pfizer$661
  • plus $4K from 32 others

What the payments were for

  • Consulting fees$1,76910%
  • Travel & lodging$1,4128%
  • Food & beverage$13,86381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,044 in reported general payments places this provider in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$549,253
Medicare patients
755
Services billed
3,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban340$332,109
EntrestoSacubitril/Valsartan257$278,715
Repatha SureclickEvolocumab188$157,202
FarxigaDapagliflozin Propanediol150$137,536
OzempicSemaglutide65$62,509
JardianceEmpagliflozin50$50,778
MultaqDronedarone Hcl38$45,877
XareltoRivaroxaban32$38,398
Repatha PushtronexEvolocumab39$33,359
Praluent PenAlirocumab35$31,270
MounjaroTirzepatide21$23,383
DapagliflozinDapagliflozin Propanediol24$17,864
InpefaSotagliflozin19$13,363
BrilintaTicagrelor12$12,097
LivaloPitavastatin Calcium23$10,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$661$332,109340 claims
NovartisEntresto$1,171$278,715257 claims
AstraZenecaFarxiga, Brilinta$120$149,633162 claims
Novo NordiskOzempic$123$62,50965 claims
Boehringer IngelheimJardiance$144$50,77850 claims
Sanofi-aventis U.S. LLCMultaq$452$45,87738 claims
Johnson & JohnsonXarelto$405$38,39832 claims
Lexicon Pharmaceuticals, Inc.Inpefa$212$13,36319 claims
Kowa Pharmaceuticals America, Inc.Livalo$28$10,50523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →